Arthralgia and myalgias associated with aromatase inhibitors: Frequency and characterization in real-life patients

被引：0
|
作者：
Camejo, Natalia
Castillo, Cecilia
Santana, Diego
Argenzio, Lucia
Amarillo, Dahiana
Herrera, Guadalupe
Guerrina, Maria
Krygier, Gabriel David
机构：
[1] Univ Uruguay, Hosp Clin, Serv Oncol Clin, Montevideo, Uruguay
[2] Hosp Clin Montevideo, Montevideo, Uruguay
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12504
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-life data on the tolerability of SGLT2 inhibitors in elderly patients with heart failure
    Hacil, A.
    Hanon, O.
    Vidal, J.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [32] Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis
    J. Hiltunen
    P. Parmanne
    T. Sokka
    T. Lamberg
    P. Isomäki
    O. Kaipiainen-Seppänen
    R. Peltomaa
    T. Uutela
    L. Pirilä
    K. Taimen
    M. J. Kauppi
    T. Yli-Kerttula
    R. Tuompo
    H. Relas
    S. Kortelainen
    K. Paalanen
    J. Asikainen
    P. Ekman
    A. Santisteban
    K.-L. Vidqvist
    K. Tadesse
    M. Romu
    J. Borodina
    P. Elfving
    H. Valleala
    M. Leirisalo-Repo
    V. Rantalaiho
    H. Kautiainen
    T. S. Jokiranta
    K. K. Eklund
    Rheumatology International, 2022, 42 : 1015 - 1025
  • [33] Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis
    Hiltunen, J.
    Parmanne, P.
    Sokka, T.
    Lamberg, T.
    Isomaki, P.
    Kaipiainen-Seppanen, O.
    Peltomaa, R.
    Uutela, T.
    Pirila, L.
    Taimen, K.
    Kauppi, M. J.
    Yli-Kerttula, T.
    Tuompo, R.
    Relas, H.
    Kortelainen, S.
    Paalanen, K.
    Asikainen, J.
    Ekman, P.
    Santisteban, A.
    Vidqvist, K-L
    Tadesse, K.
    Romu, M.
    Borodina, J.
    Elfving, P.
    Valleala, H.
    Leirisalo-Repo, M.
    Rantalaiho, V
    Kautiainen, H.
    Jokiranta, T. S.
    Eklund, K. K.
    RHEUMATOLOGY INTERNATIONAL, 2022, 42 (06) : 1015 - 1025
  • [34] Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting
    Skribek, Marcus
    Rounis, Konstantinos
    Makrakis, Dimitrios
    Agelaki, Sofia
    Mavroudis, Dimitris
    De Petris, Luigi
    Ekman, Simon
    Tsakonas, Georgios
    CANCERS, 2020, 12 (12) : 1 - 13
  • [35] Sodium-glucose cotransporter 2 inhibitors in real-life patients at high cardiovascular risk
    Cesaro, Arturo
    Fimiani, Fabio
    Gragnano, Felice
    Moscarella, Elisabetta
    Signore, Giovanni
    Maratea, Anna Chiara
    Rotolo, Francesco Paolo
    Vergara, Andrea
    Schiavo, Alessandra
    Calabro, Paolo
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (SUPPL G)
  • [36] Sodium-glucose cotransporter 2 inhibitors in real-life patients at high cardiovascular risk
    Cesaro, Arturo
    Fimiani, Fabio
    Gragnano, Felice
    Moscarella, Elisabetta
    Signore, Giovanni
    Maratea, Anna Chiara
    Rotolo, Francesco Paolo
    Vergara, Andrea
    Schiavo, Alessandra
    Calabro, Paolo
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0G)
  • [37] Real-life single centre experience on the effectiveness of emicizumab prophylaxis in patients with haemophilia A with and without inhibitors associated with improvement of health-related quality of life
    Sorbello, C. M. C.
    Grasso, S.
    Markovic, U.
    Sapuppo, G.
    Santuccio, G.
    Di Raimondo, F.
    Giuffrida, G.
    HAEMOPHILIA, 2024, 30 : 94 - 95
  • [38] A prospective real-life study of quality of life in patients with acromegaly
    Badia, X
    Webb, S
    Caron, P
    Colao, A
    Carvalho, D
    Kadioglu, P
    Reincke, M
    Pokrajac-Simeunovic, A
    Tsagarakis, S
    Johnson, I
    Caglio, S
    Vincenzi, B
    VALUE IN HEALTH, 2005, 8 (06) : A117 - A118
  • [39] Real-life incidence of cardiotoxicity and associated risk factors in sarcoma patients receiving doxorubicin
    Vitfell-Rasmussen, Joanna
    Krarup-Hansen, Anders
    Vaage-Nilsen, Merete
    Kumler, Thomas
    Zerahn, Bo
    ACTA ONCOLOGICA, 2022, 61 (07) : 801 - 808
  • [40] IS IT FEASIBLE TO WITHDRAW IMMUNOSUPPRESSIVE TREATMENT IN REAL-LIFE PATIENTS WITH ANCA-ASSOCIATED VASCULITIS?
    Monti, S.
    Vitolo, B.
    Balduzzi, S.
    Felicetti, M.
    Padoan, R.
    Berti, A.
    Bond, M.
    Quartuccio, L.
    Paolazzi, G.
    Schiavon, F.
    Montecucco, C.
    Caporali, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1491 - 1491
12345